Cargando…
Autoantibody profiling to follow evolution of lupus syndromes
INTRODUCTION: Identification of patients who are in early stages of lupus is currently done through clinical evaluation and is not greatly facilitated by available diagnostic tests. Profiling for patient characteristics and antibody specificities that predict disease would enhance the ability of phy...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580568/ https://www.ncbi.nlm.nih.gov/pubmed/22838636 http://dx.doi.org/10.1186/ar3927 |
_version_ | 1782260278692413440 |
---|---|
author | Olsen, Nancy J Li, Quan-Zhen Quan, Jiexia Wang, Ling Mutwally, Azza Karp, David R |
author_facet | Olsen, Nancy J Li, Quan-Zhen Quan, Jiexia Wang, Ling Mutwally, Azza Karp, David R |
author_sort | Olsen, Nancy J |
collection | PubMed |
description | INTRODUCTION: Identification of patients who are in early stages of lupus is currently done through clinical evaluation and is not greatly facilitated by available diagnostic tests. Profiling for patient characteristics and antibody specificities that predict disease would enhance the ability of physicians to identify and treat early cases prior to onset of organ damaging illness. METHODS: A group of 22 patients with 4 or fewer diagnostic criteria for lupus were studied for changes in clinical and autoantibody profiles after a mean follow up period of 2.4 years. An array with more than 80 autoantigens was used to profile immunoglobulin G (IgG) and immunoglobulin M (IgM) autoantibodies. Correlations with clinical disease progression were examined. RESULTS: 3 of the 22 patients (14%) added sufficient criteria during follow up to satisfy a diagnosis of systemic lupus erythematosus (SLE) or to acquire a diagnosis of SLE renal disease. Patients who progressed were all females and were younger than those who did not progress (P=0.00054). IgG but not IgM autoreactivity showed greater increases in the progressor group than in the non-progressor group (P=0.047). IgG specificities that were higher at baseline in progressors included proliferating cell nuclear antigen (PCNA), beta 2 microglobulin, C1q and hemocyanin (P<0.019). Progressors had significant increases in La/SSB and liver cytosol type 1 (LC1) IgG autoantibodies over the period of evaluation (P≤0.0072). A quantitative risk profile generated from baseline demographic and autoantibody variables yielded highly different scores for the progressor and non-progressor groups (P=1.38 × 10(-7)) CONCLUSIONS: In addition to demographic features, autoantibody profiles using an expanded array of specificities were correlated with the risk of progressive disease in patients with lupus. These findings suggest the feasibility of developing a simple diagnostic that could be applied by nonspecialists to screen for lupus and permit effective triage for specialty care. |
format | Online Article Text |
id | pubmed-3580568 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35805682013-02-26 Autoantibody profiling to follow evolution of lupus syndromes Olsen, Nancy J Li, Quan-Zhen Quan, Jiexia Wang, Ling Mutwally, Azza Karp, David R Arthritis Res Ther Research Article INTRODUCTION: Identification of patients who are in early stages of lupus is currently done through clinical evaluation and is not greatly facilitated by available diagnostic tests. Profiling for patient characteristics and antibody specificities that predict disease would enhance the ability of physicians to identify and treat early cases prior to onset of organ damaging illness. METHODS: A group of 22 patients with 4 or fewer diagnostic criteria for lupus were studied for changes in clinical and autoantibody profiles after a mean follow up period of 2.4 years. An array with more than 80 autoantigens was used to profile immunoglobulin G (IgG) and immunoglobulin M (IgM) autoantibodies. Correlations with clinical disease progression were examined. RESULTS: 3 of the 22 patients (14%) added sufficient criteria during follow up to satisfy a diagnosis of systemic lupus erythematosus (SLE) or to acquire a diagnosis of SLE renal disease. Patients who progressed were all females and were younger than those who did not progress (P=0.00054). IgG but not IgM autoreactivity showed greater increases in the progressor group than in the non-progressor group (P=0.047). IgG specificities that were higher at baseline in progressors included proliferating cell nuclear antigen (PCNA), beta 2 microglobulin, C1q and hemocyanin (P<0.019). Progressors had significant increases in La/SSB and liver cytosol type 1 (LC1) IgG autoantibodies over the period of evaluation (P≤0.0072). A quantitative risk profile generated from baseline demographic and autoantibody variables yielded highly different scores for the progressor and non-progressor groups (P=1.38 × 10(-7)) CONCLUSIONS: In addition to demographic features, autoantibody profiles using an expanded array of specificities were correlated with the risk of progressive disease in patients with lupus. These findings suggest the feasibility of developing a simple diagnostic that could be applied by nonspecialists to screen for lupus and permit effective triage for specialty care. BioMed Central 2012 2012-07-27 /pmc/articles/PMC3580568/ /pubmed/22838636 http://dx.doi.org/10.1186/ar3927 Text en Copyright ©2012 Olsen et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Olsen, Nancy J Li, Quan-Zhen Quan, Jiexia Wang, Ling Mutwally, Azza Karp, David R Autoantibody profiling to follow evolution of lupus syndromes |
title | Autoantibody profiling to follow evolution of lupus syndromes |
title_full | Autoantibody profiling to follow evolution of lupus syndromes |
title_fullStr | Autoantibody profiling to follow evolution of lupus syndromes |
title_full_unstemmed | Autoantibody profiling to follow evolution of lupus syndromes |
title_short | Autoantibody profiling to follow evolution of lupus syndromes |
title_sort | autoantibody profiling to follow evolution of lupus syndromes |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580568/ https://www.ncbi.nlm.nih.gov/pubmed/22838636 http://dx.doi.org/10.1186/ar3927 |
work_keys_str_mv | AT olsennancyj autoantibodyprofilingtofollowevolutionoflupussyndromes AT liquanzhen autoantibodyprofilingtofollowevolutionoflupussyndromes AT quanjiexia autoantibodyprofilingtofollowevolutionoflupussyndromes AT wangling autoantibodyprofilingtofollowevolutionoflupussyndromes AT mutwallyazza autoantibodyprofilingtofollowevolutionoflupussyndromes AT karpdavidr autoantibodyprofilingtofollowevolutionoflupussyndromes |